Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes

AIMS: The EMPA‐REG OUTCOME study showed reduced mortality and hospitalization due to heart failure (HF) in diabetic patients treated with empagliflozin. Overexpression and Ca(2+)‐dependent activation of Ca(2+)/calmodulin‐dependent kinase II (CaMKII) are hallmarks of HF, leading to contractile dysfun...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustroph, Julian, Wagemann, Olivia, Lücht, Charlotte M., Trum, Maximilian, Hammer, Karin P., Sag, Can Martin, Lebek, Simon, Tarnowski, Daniel, Reinders, Jörg, Perbellini, Filippo, Terracciano, Cesare, Schmid, Christof, Schopka, Simon, Hilker, Michael, Zausig, York, Pabel, Steffen, Sossalla, Samuel T., Schweda, Frank, Maier, Lars S., Wagner, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073019/
https://www.ncbi.nlm.nih.gov/pubmed/30117720
http://dx.doi.org/10.1002/ehf2.12336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073019/
https://www.ncbi.nlm.nih.gov/pubmed/30117720
http://dx.doi.org/10.1002/ehf2.12336

Ejemplares similares